Chiral and Dual Drugs Combination Reduces Tumor-Associated Neutrophils-Induced T-Cell Immunoparalysis to Treat Epithelial Ovarian Cancer
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c00681 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Yi Lai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traditional Chinese Medicine, Department of Head and Neck Surgery, Renji Hospital, School of Medicine, School of Physics and Astronomy,…. Hauptthemen laut MEDLINE: Neutrophils, Flavonoids, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Medical innovation research Project of Science and Technology Innovation Action Plan of Shanghai Municipal Science and Technology Commission.
Abstract (Originalsprache)
In antitumor activities, baicalin and astragaloside IV inhibit tumor growth, induce cell death, and restrain metastasis in various cancers. Generally, a mixture of massive herbs like scutellaria or astragalus matches with other drugs to reach a curative effect in traditional Chinese prescription. Therefore, researchers aspire to an effective type of drug combination that shows promoted absorption and higher bioavailability in preclinical studies. Here, we report an optical method to detect chiral baicalin and astragaloside IV and also monitor the absorption of different chirals in ovarian cells. Eventually, R-Baicalin-Astragaloside IV dual drugs combination shows promoted absorption of each other compared with single chiral drugs or another. Based on the optical method results, we designed a series of in vitro and in vivo experiments to explain and analyze the mechanism of the curative effect. Therein, the result reveals that the tumor-associated neutrophils were reduced via the down-regulated TLR4/MYD88/NF-κB pathway to increased PD-1/PD-L1 immune response in epithelial ovarian cancer under the influence of R-Baicalin-Astragaloside IV. Thus, this work offers a comprehensive report on structure-activity relationships of chiral and dual drug strategies to improve its bioavailability in therapy of ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Traditional Chinese Medicine, Department of Head and Neck Surgery, Renji Hospital, School of Medicine, School of Physics and Astronomy, Shanghai Jiao Tong University, No. 160 Pujian Road and No. 800 Dongch…
- State Key Laboratory of Advanced Optical Communication Systems and Networks, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Shanghai 200240, China.
- Collaborative Innovation Center of Light Manipulations and Applications, Shandong Normal University, Jinan 250358, China.
ORCID-Profile: Hailang Dai, He Li
Förderung
- Medical innovation research Project of Science and Technology Innovation Action Plan of Shanghai Municipal Science and Technology Commission
Zitieren
APA
Lai, Y., Ru, D., Dai, H., Ding, C., Ding, L., Wang, C., Luo, C., Qi, Y., Chen, X., & Li, H. (2026). Chiral and Dual Drugs Combination Reduces Tumor-Associated Neutrophils-Induced T-Cell Immunoparalysis to Treat Epithelial Ovarian Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00681
Vancouver
Lai Y, Ru D, Dai H, Ding C, Ding L, Wang C, et al. Chiral and Dual Drugs Combination Reduces Tumor-Associated Neutrophils-Induced T-Cell Immunoparalysis to Treat Epithelial Ovarian Cancer. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c00681
BibTeX
@article{Lai2026,
author = {Lai, Yi and Ru, Dan and Dai, Hailang and Ding, Chenhuan and Ding, Ling and Wang, Chen and Luo, Cenxin and Qi, Yujie and Chen, Xianfeng and Li, He},
title = {Chiral and Dual Drugs Combination Reduces Tumor-Associated Neutrophils-Induced T-Cell Immunoparalysis to Treat Epithelial Ovarian Cancer},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c00681}
}
EUVIMED